Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

187 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Targeting PIKfyve-driven lipid homeostasis as a metabolic vulnerability in pancreatic cancer.
Cheng C, Hu J, Mannan R, Bhattacharyya R, Rossiter NJ, Magnuson B, Wisniewski JP, Zheng Y, Xiao L, Li C, Awad D, He T, Bao Y, Zhang Y, Cao X, Wang Z, Mehra R, Morlacchi P, Sahai V, di Magliano MP, Shah YM, Ding K, Qiao Y, Lyssiotis CA, Chinnaiyan AM. Cheng C, et al. Among authors: mannan r. bioRxiv [Preprint]. 2024 Mar 20:2024.03.18.585580. doi: 10.1101/2024.03.18.585580. bioRxiv. 2024. PMID: 38562800 Free PMC article. Preprint.
Genomics driven precision oncology in advanced biliary tract cancer improves survival.
Kumar-Sinha C, Vats P, Tran N, Robinson DR, Gunchick V, Wu YM, Cao X, Ning Y, Wang R, Rabban E, Bell J, Shankar S, Mannan R, Zhang Y, Zalupski MM, Chinnaiyan AM, Sahai V. Kumar-Sinha C, et al. Among authors: mannan r. Neoplasia. 2023 Aug;42:100910. doi: 10.1016/j.neo.2023.100910. Epub 2023 May 31. Neoplasia. 2023. PMID: 37267699 Free PMC article.
Clinically relevant humanized mouse models of metastatic prostate cancer to evaluate cancer therapies.
Kostlan RJ, Phoenix JT, Budreika A, Ferrari MG, Khurana N, Cho JE, Juckette K, McCollum BL, Moskal R, Mannan R, Qiao Y, Griend DJV, Chinnaiyan AM, Kregel S. Kostlan RJ, et al. Among authors: mannan r. bioRxiv [Preprint]. 2023 Oct 17:2023.10.13.562280. doi: 10.1101/2023.10.13.562280. bioRxiv. 2023. Update in: Mol Cancer Res. 2024 Sep 4;22(9):826-839. doi: 10.1158/1541-7786.MCR-23-0904. PMID: 37904960 Free PMC article. Updated. Preprint.
Targeting the mSWI/SNF Complex in POU2F-POU2AF Transcription Factor-Driven Malignancies.
He T, Xiao L, Qiao Y, Klingbeil O, Young E, Wu XS, Mannan R, Mahapatra S, Eyunni S, Ching-Yi Tien J, Wang X, Zheng Y, Kim N, Zheng H, Hou S, Su F, Miner SJ, Mehra R, Cao X, Abbineni C, Samajdar S, Ramachandra M, Parolia A, Vakoc CR, Chinnaiyan AM. He T, et al. Among authors: mannan r. bioRxiv [Preprint]. 2024 May 24:2024.01.22.576669. doi: 10.1101/2024.01.22.576669. bioRxiv. 2024. Update in: Cancer Cell. 2024 Aug 12;42(8):1336-1351.e9. doi: 10.1016/j.ccell.2024.06.006. PMID: 38328238 Free PMC article. Updated. Preprint.
Development of an orally bioavailable mSWI/SNF ATPase degrader and acquired mechanisms of resistance in prostate cancer.
He T, Cheng C, Qiao Y, Cho H, Young E, Mannan R, Mahapatra S, Miner SJ, Zheng Y, Kim N, Zeng VZ, Wisniewski JP, Hou S, Jackson B, Cao X, Su F, Wang R, Chang Y, Kuila B, Mukherjee S, Dukare S, Aithal KB, D S S, Abbineni C, Lyssiotis CA, Parolia A, Xiao L, Chinnaiyan AM. He T, et al. Among authors: mannan r. bioRxiv [Preprint]. 2024 Mar 2:2024.02.29.582768. doi: 10.1101/2024.02.29.582768. bioRxiv. 2024. Update in: Proc Natl Acad Sci U S A. 2024 Apr 9;121(15):e2322563121. doi: 10.1073/pnas.2322563121. PMID: 38464081 Free PMC article. Updated. Preprint.
NSD2 is a requisite subunit of the AR/FOXA1 neo-enhanceosome in promoting prostate tumorigenesis.
Parolia A, Eyunni S, Verma BK, Young E, Liu L, George J, Aras S, Das CK, Mannan R, Rasool RU, Luo J, Carson SE, Mitchell-Velasquez E, Liu Y, Xiao L, Gajjala PR, Jaber M, Wang X, He T, Qiao Y, Pang M, Zhang Y, Alhusayan M, Cao X, Tavana O, Hou C, Wang Z, Ding K, Chinnaiyan AM, Asangani IA. Parolia A, et al. Among authors: mannan r. bioRxiv [Preprint]. 2024 Mar 29:2024.02.22.581560. doi: 10.1101/2024.02.22.581560. bioRxiv. 2024. Update in: Nat Genet. 2024 Oct;56(10):2132-2143. doi: 10.1038/s41588-024-01893-6. PMID: 38464251 Free PMC article. Updated. Preprint.
CDK12 Loss Promotes Prostate Cancer Development While Exposing Vulnerabilities to Paralog-Based Synthetic Lethality.
Tien JC, Chang Y, Zhang Y, Chou J, Cheng Y, Wang X, Yang J, Mannan R, Shah P, Wang XM, Todd AJ, Eyunni S, Cheng C, Rebernick RJ, Xiao L, Bao Y, Neiswender J, Brough R, Pettitt SJ, Cao X, Miner SJ, Zhou L, Wu YM, Labanca E, Wang Y, Parolia A, Cieslik M, Robinson DR, Wang Z, Feng FY, Lord CJ, Ding K, Chinnaiyan AM. Tien JC, et al. Among authors: mannan r. bioRxiv [Preprint]. 2024 Mar 21:2024.03.20.585990. doi: 10.1101/2024.03.20.585990. bioRxiv. 2024. Update in: Cell Rep Med. 2024 Oct 15;5(10):101758. doi: 10.1016/j.xcrm.2024.101758. PMID: 38562774 Free PMC article. Updated. Preprint.
p300/CBP degradation is required to disable the active AR enhanceosome in prostate cancer.
Luo J, Chen Z, Qiao Y, Tien JC, Young E, Mannan R, Mahapatra S, He T, Eyunni S, Zhang Y, Zheng Y, Su F, Cao X, Wang R, Cheng Y, Seri R, George J, Shahine M, Miner SJ, Vaishampayan U, Wang M, Wang S, Parolia A, Chinnaiyan AM. Luo J, et al. Among authors: mannan r. bioRxiv [Preprint]. 2024 May 23:2024.03.29.587346. doi: 10.1101/2024.03.29.587346. bioRxiv. 2024. PMID: 38586029 Free PMC article. Preprint.
187 results